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INTRODUCTION 
Esophagogastric junction outflow obstruction (EGJOO) is a rare but increasingly recognized 
diagnosis as described by The Chicago Classification of Esophageal Motility Disorders version 
3.0 (CC v3.0)1. On high-resolution manometry (HRM), EGJOO is characterized by elevated 
integrated relaxation pressure (IRP) of the lower esophageal sphincter (LES), yet with some 
preserved esophageal peristalsis2–4. Little consensus exists on the preferred therapeutic 
approach3. Although conceptually POEM should address the measurable dysfunction in the LES, 
few data exist to support this5. Thus, we aimed to evaluate the safety and efficacy of POEM for 
the treatment of symptomatic EGJOO.  
METHODS 
This is a multicenter retrospective analysis of patients with symptomatic EGJOO who underwent 
POEM between Feb-2014 and Feb-2020. Institutional Review Board approval was obtained at 
each institution (6 U.S., 1 from Italy). POEM was performed as previously described5. All 
patients underwent pre-POEM HRM and upper endoscopy. Technical and clinical success 
defined as completion of the POEM and post-POEM Eckardt score ≤ 3 without additional 
interventions, respectively. Adverse events were graded based on the ASGE lexicon6.  
RESULTS 
Fifty-five patients underwent POEM for EGJOO (Table 1). Mean duration of symptoms prior to 
POEM was 70.1 months. Nearly half of patients (45.5%) had failed prior treatment. The mean 
baseline Eckardt score and IRP were 7.1 ± 2.64 and 25.34 ± 26.25 mmHg, respectively. 
Functional lumen imaging probe (FLIP) was abnormal in 88.2% of patients. Barium retention on 
esophagram was seen in 95.6%. 
Technical success was achieved in all patients (100%) with mean procedure time of 73.2± 35.6 
minutes (Table 1). Clinical success was attained in 47/55 patients (94%) at median follow-up of 
117 days. There were 2 minor (mucosal perforation), 2 mild (pneumoperitoneum requiring 
decompression) and 1 severe adverse event (1 mucosal perforation treated with esophageal stent 
with full recovery). Mean post-POEM IRP (n=17) was 8.88±7.03 mmHg, a mean difference of 
10.64 (95% CI 5.82-15.46; p=0.0003) from pre-POEM HRM. Post-POEM pH monitoring 
(n=18) was abnormal in 66%. Twenty-five patients had post-POEM endoscopy and esophagitis 
was seen in 10/25 (grade A 4/25, grade B 6/25, grade C or D 0/25) (Table 1).  
DISCUSSION 
Given that EGJOO defining measurable characteristic is failure of LES to relax symptomatic 
improvement after POEM is expected. Indeed, our preliminary data support POEM as an 
effective and safe therapy4. Our findings expand on earlier report in which POEM was effective 
for a variety of non-achalasia motility disorders, including EGJOO5. Noteworthy, since POEM is 
an invasive procedure that permanently disrupts the LES, accurate pre-procedure diagnosis with 
exclusion of secondary causes of mechanical obstruction is essential. Furthermore, it is important 
to highlight the dynamic nature of symptoms in EGJOO, as spontaneous resolution has been 
previously documented3. In our study, the duration of symptoms pre-POEM averaged 70 months 
with 45.5% of patients undergoing prior therapy making spontaneous resolution unlikely. As 
such, POEM should only be considered in patients with persistent symptoms, as those described 
in this study. Abnormal EndoFLIP results may identify EGJOO patients that would have high 
success with the current treatments used in achalasia, including POEM7. Thus, incorporating 
EndoFLIP data and stratifying patients based on symptoms into future prospective EGJOO 
studies is recommended7. Similarly, there is accumulating data identifying an association 
between opioids and LES mechanics, with many patients exhibiting EGJOO patterns on HRM 
when opioids were received within 24 hours1,8.  As this is investigated further, we suggest the 
discontinuation of all opioids >24 hours prior to HRM during evaluation for POEM.  
Our study is not without limitations. At this point in time, there is very limited data on the utility 
of POEM in EGJOO, thus this study serves as a proof-of-concept. There was no standardized 
pre- and post-procedure management, thus post-POEM testing was done at the discretion of the 
performing physician. Subsequently, the observed occurrence of post-POEM GERD may be 
inaccurately high due to selection bias but there is no reason to believe the frequency of post-
POEM GERD to be different for EGJOO than for achalasia.  
Nevertheless, we present the largest series to date which serves both as an aid in clinical 
decision-making and as a springboard for future higher quality studies. Furthermore, our 
multicenter data provide external validity to our findings. We did not have opioid-use data 
available, highlighting the necessity of this endpoint in future studies. Despite our relatively 
short follow-up period, it is reasonable to expect these findings to be similar to that of POEM for 
achalasia where we have well documented mid- and long-term results. Our findings support the 
possible role of POEM as safe and effective in everyday practice but also the need for further 
larger prospective studies.    
  
Table 1. Patient and procedure characteristics (n = 55) 
 Pre-POEM Post-POEM 
Age (years), mean ± SD 58.8 ± 16.09  
Female, n= (%) 33 (60)  
Male, n= (%) 22 (40)  
Duration of symptoms (months), mean ± 
SD 
70.1 ± 100.03  
Prior therapy, no. (%) 25 (45.5)  
Pharmacotherapy, total n= (%) 10 (18.0) 2 (3.6) 
Botulinum toxin injections, total n= (%) 15 (27.0) 0 (0.0) 
Pneumatic dilation, total n= (%) 12 (22.0) 1 (1.8) 
Surgical myotomy, n= (%) 0 (0.0) 1 (1.8) 
Pharmacotherapy and botulinum toxin 
injection, n= (%) 
7 (13.0) 0 (0.0) 
Pharmacotherapy, botulinum toxin 
injection, and pneumatic dilation, n= (%) 
3 (5.0) 0 (0.0) 
Botulinum toxin injections and 
pneumatic dilation, n= (%) 
1 (1.8) 0 (0.0) 
Esophagitis on endoscopy, n/N= (%) Grade A 2/55 (2.0) 
Grade B 0/55 (0.0) 
Grade C 0/55 (0.0) 
Grade D 0/55 (0.0) 
Grade A 4/25 (16.0) 
Grade B 6/25 (24.0) 
Grade C 0/25 (0) 
Grade D 0/25 (0) 
IRP (mmHg), mean ± SD 25.34 ± 26.25  8.88 ± 7.03 
Difference from pre- to post-POEM IRP 
(mmHg), mean (95%CI; p-value) 
 10.64 
(5.82-15.46, 0.0003) 
Eckardt score, mean ± SD  
Distribution 
- Score 0-1 
- Score 2-3 
- Score >3 










Abnormal EndoFLIP (EGJ-DI ≤ 2.8 
mm2/mmHg), n/N= (%) 
15/17 (88.2)  
Barium Esophagram 
- Retention of liquids n/N= (%) 






Procedural time (minutes), mean ± SD  73.2 ± 35.6 
Anterior/Posterior approach, n (%)  28 (50.9) / 27 (49.0) 
Total myotomy length (cm), mean ± SD  12.58 ± 3.33 
Post-procedural results 
Technical success, n (%)  55 (100) 
Successful clinical response, n (%)  47 (94.0) 
Adverse events, n  Minor: 2/55 
Mild: 2/55  
Severe: 1/55 
Adverse events, n (%)  5 (9.6) 
Revision of POEM, n (%)  1 (1.8) 
Abnormal time pH >4 on 24-hour pH 
monitoring, n/N (%) 
 12/18 (66.6) 
Duration of follow-up (days), median 
(IQR) 
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